Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 9;8(8):CD006751.
doi: 10.1002/14651858.CD006751.pub5.

Vitamin A and beta (β)-carotene supplementation for cystic fibrosis

Jorrit Jv de Vries  1 , Anne B Chang, Catherine M Bonifant, Elizabeth Shevill, Julie M Marchant
Affiliations

Vitamin A and beta (β)-carotene supplementation for cystic fibrosis

Jorrit Jv de Vries et al. Cochrane Database Syst Rev. .

Abstract

Background: People with cystic fibrosis (CF) and pancreatic insufficiency are at risk of a deficiency in fat-soluble vitamins, including vitamin A. Vitamin A deficiency predominantly causes eye and skin problems, while excessive levels of vitamin A can harm the respiratory and skeletal systems in children and interfere with the metabolism of other fat-soluble vitamins. Most CF centres administer vitamin A as supplements to reduce the frequency of vitamin A deficiency in people with CF and to improve clinical outcomes such as growth, although the recommended dose varies between different guidelines. Thus, a systematic review on vitamin A and vitamin A-like supplementation (carotenes or other retinoids) in people with CF would help guide clinical practice. This is an update of an earlier Cochrane Review.

Objectives: To determine if supplementation with vitamin A, carotenes or other retinoid supplements in children and adults with CF reduces the frequency of vitamin A deficiency disorders, improves general and respiratory health and affects the frequency of vitamin A toxicity.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Cystic Fibrosis Trials Register compiled from electronic database searches and handsearching of journals and conference abstract books. Additionally we searched several ongoing trials registries, including ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform and the International Standard Randomised Controlled Trial Number Registry.Most recent database searches: 01 June 2018.

Selection criteria: All randomised or quasi-randomised controlled studies comparing all preparations of oral vitamin A, carotenes or retinoids (or in combination), used as a supplement compared to placebo at any dose, for at least three months, in people with CF (diagnosed by sweat tests or genetic testing) with and without pancreatic insufficiency.

Data collection and analysis: Two authors individually assessed study quality and extracted data on outcome measures. The authors assessed the quality of the evidence using the GRADE system. Investigators were contacted to retrieve missing quantitative data.

Main results: No studies of vitamin A or other retinoid supplementation were eligible for inclusion. However, one randomised study of beta (β)-carotene supplementation involving 24 people with CF who were receiving pancreatic enzyme substitution was included. The study compared successive β-carotene supplementation periods (high dose followed by low dose) compared to placebo. The results for the low-dose supplementation period should be interpreted with caution, due to the lack of a wash-out period after the high-dose supplementation.The included study did not report on two of the review's primary outcomes (vitamin A deficiency disorders and mortality); results for our third primary outcome of growth and nutritional status (reported as z score for height) showed no difference between supplementation and placebo, mean difference (MD) -0.23 (95% confidence interval (CI) -0.89 to 0.43) (low-quality evidence). With regards to secondary outcomes, supplementation with high-dose β-carotene for three months led to significantly fewer days of systemic antibiotics required to treat pulmonary exacerbations, compared to controls, MD -15 days (95% CI -27.60 to -2.40); however, this was not maintained in the second three-month section of the study when the level of β-carotene supplementation was reduced, MD -8 days (95% CI -18.80 to 2.80) (low-quality evidence). There were no statistically significant effects between groups in lung function (low-quality evidence) and no adverse events were observed (low-quality evidence). Supplementation affected levels of β-carotene in plasma, but not vitamin A levels. The study did not report on quality of life or toxicity.

Authors' conclusions: Since no randomised or quasi-randomised controlled studies on retinoid supplementation were identified, no conclusion on the supplementation of vitamin A in people with CF can be drawn. Additionally, due to methodological limitations in the included study, also reflected in the low-quality evidence judged following the specific evidence grading system (GRADE), no clear conclusions on β-carotene supplementation can be drawn. Until further data are available, country- or region-specific guidelines regarding these practices should be followed.

PubMed Disclaimer

Conflict of interest statement

Catherine Bonifant has no potential conflict of interest.

Anne Chang declares the receipt of a grant provided by GSK, which is, however, unrelated to this topic.

Elizabeth Shevill has no potential conflict of interest.

Jorrit de Vries has no potential conflict of interest.

Julie Marchant has no potential conflict of interest.

Figures

1
1
Study flow diagram
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for the included study.
1.1
1.1. Analysis
Comparison 1: β‐carotene supplementation versus placebo, Outcome 1: Growth and nutritional status: z score for height
1.2
1.2. Analysis
Comparison 1: β‐carotene supplementation versus placebo, Outcome 2: Respiratory outcomes: FEV1 (% predicted)
1.3
1.3. Analysis
Comparison 1: β‐carotene supplementation versus placebo, Outcome 3: Respiratory outcomes: antibiotic days per patient in past 3 months
1.4
1.4. Analysis
Comparison 1: β‐carotene supplementation versus placebo, Outcome 4: Plasma concentrations: vitamin A [µmol/L]
1.5
1.5. Analysis
Comparison 1: β‐carotene supplementation versus placebo, Outcome 5: Plasma concentrations: β‐carotene [µmol/L]
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Rust 1998 {published data only}
    1. Engl B, Rust P, Eichler I, Renner S, Elmadfa I. Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months [Bioverfugbarkeit einer therapeutischen Beta-Carotin (BC) Gabe bei Patienten mit zystischer Fibrose (CF) und Auswirkungen auf anthropometrische Parameter uber eine Versuchsdauer von 6 Monaten]. Monatsschrift fur Kinderheilkunde 1997; 145:S 134. [CENTRAL: 336058] [CFGD REGISTER: GN69g]
    1. Renner S, Rath R, Rust P, Lehr S, Frischer T, Elmadfa I, et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax 2001; 56(1):48-52. [CENTRAL: 329478] [CFGD REGISTER: GN69f] [PMID: ] - PMC - PubMed
    1. Renner S, Wojnarowski C, Koller DY, Rust P, Elmadfa I, Eichler I. Patients with cystic fibrosis (CF) benefit from β-carotene supplementation for 6 months. Pediatric Pulmonology 1997; Suppl 14:314. [CENTRAL: 794966] [CFGD REGISTER: GN69a]
    1. Renner S, Wojnarowski C, Koller DY, Rust P, Elmadfa I, Eichler I. Patients with cystic fibrosis (CF) benefit from beta-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CENTRAL: 794967] [CFGD REGISTER: GN69b]
    1. Rust P, Eichler I, Elmadfa I. Influence of an oral beta-carotine-supplementation on the antioxidant status of patients with cystic fibrosis [Einfluss einer oralen beta-Karotin-Supplementierung auf den Antioxidantienstatus von Patienten mit zystischer Fibrose]. Atemwegs und Lungenkrankheiten 1997; 23:51. [CENTRAL: 255854] [CFGD REGISTER: GN69d]

References to studies excluded from this review

Cobanoglu 2002 {published data only}
    1. Cobanoğlu N, Ozçelik U, Göçmen A, Kiper N, Doğru D. Antioxidant effect of beta-carotene in cystic fibrosis and bronchiectasis: clinical and laboratory parameters of a pilot study. Acta Paediatrica 2002; 91(7):793-8. [CFGD REGISTER: GN99] [PMID: ] - PubMed
Garić 2015 {published and unpublished data}
    1. Garić D, De Sanctis J, Wojewodka G, Houle D, Cupri S, Hajduch M, et al. Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside. Journal of Molecular Medicine (Berlin, Germany) 2017; 95(10):1053-64. - PubMed
    1. Garic D, Wojewodka G, De Sanctis JB, Hajduch M, Kopriva F, Pislariu R, et al. Fenretinide treatment increases long chain ceramide C24:0 and decreases short chain ceramide C16:0 levels in patients with cystic fibrosis (phase IB clinical trial). Pediatric pulmonology 2015; 50 Suppl 41:291. [ABSTRACT NO: 264] [CFGD REGISTER: GN253b]
    1. Radzioch D, Wojewodka G, Cupri S, Colin P, Pislariu R, Garić D, et al. A novel oral formulation of fenretinide demonstrates safety and tolerability in a phase 1B dose-ascending trial involving adult cystic fibrosis patients. Pediatric Pulmonology 2015; 50 Suppl 41:290. [ABSTRACT NO: 261 ] [CFGD REGISTER: GN253c]
    1. Wojewodka G, Matouk E, De Sanctis JB, Pislariu R, Colin P, Matin C, et al. The cystic fibrosis associated fatty acid imbalance is corrected by a novel formulation of fenretinide in a phase 1B clinical trial. Pediatric Pulmonology 2015; 50 Suppl 41:289. [ABSTRACT NO: 260 ] [CFGD REGISTER: GN253a]
Homnick 1995 {published data only}
    1. Homnick DN, Spillers CR, Cox SR, Cox JH, Yelton LA, De Loof MJ, et al. Single- and multiple-dose response relationships of beta-carotene in cystic fibrosis. Journal of Pediatrics 1995; 127(3):491-4. [CFGD REGISTER: GN68] [PMID: ] - PubMed
NCT01859390 {published data only}
    1. NCT01859390. Effects of an antioxidant-enriched multivitamin supplement on inflammation and oxidative stress in cystic fibrosis (AquADEKs-2) [A multi-center, randomized, controlled, double-blind study of the effects of an antioxidant-enriched multivitamin supplement on inflammation and oxidative stress in cystic fibrosis patients]. clinicaltrials.gov/ct2/show/NCT01859390 (first received 21 May 2013).
Wood 2003 {published data only}
    1. Wood LG, Fitzgerald DA, Lee AK, Garg ML. Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. American Journal of Clinical Nutrition 2003; 77(1):150-9. [CFGD REGISTER: GN98] [PMID: ] - PubMed

Additional references

Bjelakovic 2013
    1. Bjelakovic G, Nikolova D, Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PloS one 2013; 8(9):e74558. [DOI: 10.1371/journal.pone.0074558] [PMID: ] - DOI - PMC - PubMed
Borowitz 2002
    1. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2002; 35(3):246-59. [PMID: ] - PubMed
Brei 2013
    1. Brei C, Simon A, Krawinkel MB, Naehrlich L. Individualized vitamin A supplementation for patients with cystic fibrosis. Clinical Nutrition (Edinburgh, Scotland) 2013; 32(5):805-10. [DOI: 10.1016/j.clnu.2013.01.009] [PMID: ] - DOI - PubMed
Burri 2001
    1. Burri BJ, Neidlinger TR, Clifford AJ. Serum carotenoid depletion follows first-order kinetics in healthy adult women fed naturally low carotenoid diets. Journal of nutrition 2001; 131(8):2096-100. [PMID: ] - PubMed
Cantin 2007
    1. Cantin AM, White TB, Cross CE, Forman HJ, Sokol RJ, Borowitz D. Antioxidants in cystic fibrosis. Conclusions from the CF Antioxidant Workshop, Bethesda, Maryland, November 11-12, 2003. Free Radical Biology and Medicine 2007; 42(1):15-31. [DOI: 10.1016/j.freeradbiomed.2006.09.022] [PMID: ] - DOI - PMC - PubMed
Cates 2003 [Computer program]
    1. Visual Rx. Online NNT Calculator. Version 4. Cates C, 2016.Available at www.nntonline.net/.
CDC 2012
    1. Centers for Disease Control and Prevention. Second national report on biochemical indicators of diet and nutrition in the U.S. population 2012; 2012 April. www.cdc.gov/nutritionreport/report.html (accessed prior to 08 November 2017). [https://www.cdc.gov/nutritionreport/report.html]
CF Trust 2016
    1. UK Cystic Fibrosis Trust Nutrition Working Group. Nutritional management of cystic fibrosis. UK Cystic Fibrosis Trust Consensus Document on Nutritional Management 2016.
Chang 2006
    1. Chang AB, Torzillo PJ, Boyce NC, White AV, Stewart PA, Wheaton GR, et al. Zinc and vitamin A supplementation in Indigenous Australian children hospitalised with lower respiratory tract infection: a randomised controlled trial. Medical Journal of Australia 2006; 184(3):107-12. [PMID: ] - PubMed
Ciofu 2014
    1. Ciofu O, Lykkesfeldt J. Antioxidant supplementation for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD007020.pub3] [PMID: ] - DOI - PubMed
Dodge 2006
    1. Dodge JA, Turck D. Cystic fibrosis: nutritional consequences and management. Best Practice & Research. Clinical Gastroenterology 2006; 20(3):531-46. [DOI: 10.1016/j.bpg.2005.11.006] [PMID: ] - DOI - PubMed
Druesne 2010
    1. Druesne-Pecollo N, Latino-Martel P, Norat T, Barrandon E, Bertrais S, Galan P, et al. Beta-carotene supplementation and cancer risk: a systematic review and meta-analysis of randomized controlled trials. International Journal of Cancer 2010; 127(1):172-84. [DOI: 10.1002/ijc.25008] [PMID: ] - DOI - PubMed
Dueker 2000
    1. Dueker SR, Lin Y, Buchholz BA, Schneider PD, Lamé MW, Segall HJ, et al. Long-term kinetic study of beta-carotene, using accelerator mass spectrometry in an adult volunteer. Journal of Lipid Research 2000; 41(11):1790-800. [PMID: ] - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002; 31(1):140-9. [PMID: 11914310] - PubMed
Ferguson 2014
    1. Ferguson JH, Chang AB. Vitamin D supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD007298.pub3] [PMID: ] - DOI - PMC - PubMed
Galli 2012
    1. Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, et al. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2012; 1822(5):690-713. [DOI: 10.1016/j.bbadis.2011.12.012] [PMID: ] - DOI - PubMed
Graham‐Maar 2006
    1. Graham-Maar RC, Schall JI, Stettler N, Zemel BS, Stallings VA. Elevated vitamin A intake and serum retinol in preadolescent children with cystic fibrosis. American Journal of Clinical Nutrition 2006; 84(1):174-82. [PMID: ] - PubMed
Griffiths 2000
    1. Griffiths JK. The vitamin A paradox. Journal of Pediatrics 2000; 137(5):604-7. [PMID: ] - PubMed
Hammond 2013
    1. Hammond BR Jr, Renzi LM. Carotenoids. Advances in Nutrition 2013; 4(4):474-6. [DOI: 10.3945/an.113.004028] [PMID: ] - DOI - PMC - PubMed
Harrison 2012
    1. Harrison E. Mechanisms involved in the intestinal absorption of dietary vitamin A and provitamin A carotenoids. Biochimica et biophysica acta 2012; 1821(1):70-7. [DOI: 10.1016/j.bbalip.2011.06.002] [PMID: ] - DOI - PMC - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414):557-60. [PMID: ] - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Jagannath 2017
    1. Jagannath VA, Thaker V, Chang AB, Price AI. Vitamin K supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews 2017, Issue 8. [DOI: 10.1002/14651858.CD008482.pub5] [PMID: ] - DOI - PMC - PubMed
Krinsky 2005
    1. Krinsky NI, Johnson EJ. Carotenoid actions and their relation to health and disease. Molecular Aspects of Medicine 2005; 26(6):459-516. [PMID: ] - PubMed
Lascari 1981
    1. Lascari AD. Carotenemia. A review. Clinical Pediatrics 1981; 20(1):25-9. [PMID: ] - PubMed
Li 2016
    1. Li L, Somerset S. Dietary intake and nutritional status of micronutrients in adults with cystic fibrosis in relation to current recommendations. Clinical Nutrition 2016; 35(4):775-82. [DOI: 10.1016/j.clnu.2015.06.004] [PMID: ] - DOI - PubMed
Maqbool 2008
    1. Maqbool A, Graham-Maar RC, Schall JI, Zemel BS, Stallings VA. Vitamin A intake and elevated serum retinol levels in children and young adults with cystic fibrosis. Journal of Cystic Fibrosis 2008; 7(2):137-41. [DOI: 10.1016/j.jcf.2007.07.002] [PMID: ] - DOI - PMC - PubMed
Marchant 2001
    1. Marchant JM, Masel JP, Dickinson FL, Masters IB, Chang AB. Application of chest high-resolution computer tomography in young children with cystic fibrosis. Pediatric Pulmonology 2001; 31(1):24-9. [PMID: ] - PubMed
Napoli 1996
    1. Napoli JL. Retinoic acid biosynthesis and metabolism. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1996; 10(9):993-1001. [PMID: ] - PubMed
Okebukola 2017
    1. Okebukola PO, Kansra S, Barrett J. Vitamin E supplementation in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2017, Issue 3. [DOI: 10.1002/14651858.CD009422.pub3] [PMID: ] - DOI - PMC - PubMed
Olmedilla 2001
    1. Olmedilla B, Granado F, Southon S, Wright AJA, Blanco I, Gil-Martinez E, et al. Serum concentrations of carotenoids and vitamins A, E, and C in control subjects from five European countries. British Journal of Nutrition 2001; 85(2):227-38. [DOI: 10.1079/BJN2000248] [PMID: ] - DOI - PubMed
Paik 2001
    1. Paik J, During A, Harrison EH, Mendelsohn CL, Lai K, Blaner WS. Expression and characterization of a murine enzyme able to cleave beta-carotene. The formation of retinoids. The Journal of biological chemistry 2001; 276(34):32160-8. [DOI: 10.1074/jbc.M010086200] [PMID: ] - DOI - PubMed
Penniston 2006
    1. Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. American Journal of Clinical Nutrition 2006; 83(2):191-201. [PMID: ] - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Royal Brompton Hospital 2017
    1. Clinical Guidelines: Care of Children with Cystic Fibrosis: Royal Brompton Hospital (7th edition) 2017. www.rbht.nhs.uk/childrencf (accessed 07 February 2017).
Saxby 2017
    1. Saxby N, Painter C, Kench A, King S, Crowder T, Haak N, et al. Nutrition Guidelines for Cystic Fibrosis in Australia and New Zealand. Thoracic Society of Australia and New Zealand https://www.thoracic.org.au/documents/item/1045 (accessed 16 January 2018). - PubMed
Sethuraman 2006
    1. Sethuraman U. Vitamins. Pediatric Review 2006; 27(2):44-55. [PMID: ] - PubMed
Shenkin 2006
    1. Shenkin A. The key role of micronutrients. Clinical Nutrition 2006; 25(1):1-13. [DOI: 10.1016/j.clnu.2005.11.006] [PMID: ] - DOI - PubMed
Socha 2010
    1. Socha P, Skorupa E, Pawlowska J, Wierzbicka A, Dhawan A, Jankowska I, et al. Beta-carotene deficiency in cholestatic liver disease of childhood is caused by beta-carotene malabsorption. Journal of Pediatric Gastroenterology and Nutrition 2010; 51(1):106-9. [DOI: 10.1097/MPG.0b013e3181d1afff] [PMID: ] - DOI - PubMed
Stephensen 1994
    1. Stephensen CB, Alvarez JO, Kohatsu J, Hardmeier R, Kennedy JI Jr, Gammon RB Jr. Vitamin A is excreted in the urine during acute infection. American Journal of Clinical Nutrition 1994; 60(3):388-92. [PMID: ] - PubMed
Thürmann 2002
    1. Thürmann PA, Steffen J, Zwernemann C, Aebischer CP, Cohn W, Wendt G, et al. Plasma concentration response to drinks containing beta-carotene as carrot juice or formulated as a water dispersible powder. European Journal of Nutrition 2002; 41(5):228-35. [DOI: 10.1007/s00394-002-0381-3] [PMID: ] - DOI - PubMed
West 2003
    1. West KP Jr. Vitamin A deficiency disorders in children and women. Food and Nutrition Bulletin 2003; 24(4 Suppl):S78-90. [PMID: ] - PubMed
Wise 2009
    1. Wise JA, Kaats GR, Preuss HG, Morin RJ. beta-Carotene and alpha-tocopherol in healthy overweight adults; depletion kinetics are correlated with adiposity. International Journal of Food Sciences and Nutrition 2009; 60(Suppl 3):65-75. [DOI: 10.1080/09637480902852553] [PMID: ] - DOI - PubMed

References to other published versions of this review

Bonifant 2012
    1. Bonifant CM, Shevill E, Chang AB. Vitamin A supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD006751.pub3] [PMID: ] - DOI - PubMed
Bonifant 2014
    1. Bonifant CM, Shevill E, Chang AB. Vitamin A supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD006751.pub4] [PMID: ] - DOI - PubMed
O'Neil 2008
    1. O'Neil CM, Shevill E, Chang AB. Vitamin A supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD006751.pub2] [PMID: ] - DOI - PubMed

Publication types

MeSH terms